Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 17/20 | 0.52 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 7/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31331699 | 0.87 | AR (0.53) | ARBRPF1PGRGAAKDM4E | |
| SCHEMBL21957297 | 0.82 | AR (0.50) | ARPGRATMNR3C1NR3C2 | |
| SCHEMBL21978549 | 0.81 | AR (0.49) | ARPGRNR3C1NR3C2 | |
| SCHEMBL6023005 | 0.79 | PIK3CG (0.57) | ARPGRALDH1A1NR3C1NR3C2 | |
| SCHEMBL21957305 | 0.78 | AR (0.54) | ARPGRGAAKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL4179555 | 0.78 | AR (0.47) | ARBRPF1GAAKDM4EMEN1 | |
| SCHEMBL30349904 | 0.78 | NQO2 (0.61) | BRPF1GAAKDM4EMEN1ALDH1A1 | |
| SCHEMBL17576254 | 0.78 | NQO2 (0.61) | BRPF1GAAKDM4EMEN1ALDH1A1 | |
| SCHEMBL30901341 | 0.78 | KDM4E (0.61) | ARPGRKDM4EHPGDATM | |
| SCHEMBL5865925 | 0.78 | KDM4E (0.61) | ARPGRKDM4EHPGDATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170291875-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL BUSINESS PLC (GB) | 2017-10-12 | — | — | US | disclosed |
| EP-3189037-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL Business PLC (GB) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016034512-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL BUSINESS PLC (GB) | 2016-03-10 | — | — | WO | disclosed |
| US-7074933-B2 | Urea and thiourea derivatives | WARNER LAMBERT COMPANY LLC (US) | 2006-07-11 | — | — | US | disclosed |
| EP-1603882-A2 | UREA AND THIOUREA DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20040266820-A1 | Urea and thiourea derivatives | DU DANIEL Y (US) | 2004-12-30 | — | — | US | disclosed |
| WO-2004072044-A2 | UREA AND THIOUREA DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291875-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | BRD4, BRPF3, BRD3 | AR 4027/4885BRPF1 104/4885PGR 4590/4885 |
| US-20040266820-A1 | Urea and thiourea derivatives | SHBG, ZP1, ZYX | AR 25/4885BRPF1 2379/4885PGR 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.